P29 Inducible nitric oxide synthase (NOS 2) gene promoter polymorphism in South Indian systemic lupus erythematosus patients

Abstract

Results: Of the patients initially randomized to abatacept and entering the LTE (N = 378), 291 (77%), 290 (77%), 293 (78%), 287 (76%) and 235 (62%) patients had paired radiographs both at baseline, and at Years 1, 2, 3, 4 and 5, respectively. A reduction of approximately 50% in all scores (ES, JSN and TS) was observed in the second year relative to the first year and continued to decrease over Years 3, 4 and 5 (Table). In total, 173/291 (59.5%), 143/290 (49.3%), 134/293 (45.7%), 128/287 (44.6%) and 106/235 (45.1%) patients were non-progressors at Years 1, 2, 3, 4 and 5, respectively. Of the non-progressors at Year 1, 76% remained non- progressors at Year 2. 88% of patients who were non-progressors at Years 1 and 2, remained non-progressors at Year 3; and during the fourth year of treatment, 92% of patients who were non-progressors during Years 1-3 remained non-progressors. In this 5-year analysis, 98% of patients who were non-progressors during Years 1-4 remained non-progressors at Year 5. Mean change (SD) Genant-modified Sharp score Radiographic Baseline to Year Year Year Year assessment Year 1 1 to 2 2 to 3 3 to 4 4 to 5 (n = 291) (n = 290) (n = 293) (n = 290) (n = 233) ES 0.42 (1.20) 0.22 (0.91) 0.23 (0.93) 0.23 (0.79) 0.11 (0.66) JSN 0.38 (1.05) 0.19 (0.60) 0.14 (0.68) 0.11 (0.50) 0.14 (0.86) TS 0.80 (1.99) 0.41 (1.28) 0.37 (1.49) 0.34 (1.12) 0.26 (1.40)